

AMENDMENT TO THE CLAIMS

Please amend the claims as follows. This listing of claims will replace all prior versions and listing of claims in the application:

Listing of Claims:

1. – 9. (Canceled)

10. (Previously presented) A method for treating cancer caused by cells expressing melanotransferrin (p97) at their surface, said method comprising the step of administering to a patient in need thereof exogenous soluble p97 or active fragment thereof, [[,]]said soluble p97 or active fragment thereof being unconjugated to any moiety and competing with the p97 expressed on the cell surface, activating plasminogen in solution instead of membrane-bound plasminogen, thus preventing cell migration and preventing cancer cells from spreading.

11. – 13. (Canceled)

14. (Original) The method of claim 10, wherein said cell is a tumor cell.

15. (Original) The method of claim 10, wherein said cell is selected from the group consisting of human vascular or microvascular endothelial cells and human melanoma cells.

16. – 31. (Canceled)

32. (Previously presented) A pharmaceutical composition for use in treating cancer comprising a therapeutically effective amount of one of melanotransferrin (p97) or an active fragment thereof, said melanotransferrin or fragment thereof being unconjugated to any moiety, in association with a pharmaceutically acceptable carrier.

33. – 35. (Canceled)

36. (Original) A method of treating cancer, comprising administering to an individual a therapeutically effective amount of a pharmaceutical composition according to claim 32.

37. (Previously presented) The method according to claim 36, wherein said administering is carried out orally, parenterally, subcutaneously, intravenously, intramuscularly, intraperitoneally, intraarterially, transdermally or via a mucus membrane.

38. (Previously presented) The method according to claim 36, wherein said cancer is selected from the group consisting of melanoma, prostate cancer, leukemia, hormone dependent cancer, breast cancer, colon cancer, lung cancer, skin cancer, ovarian cancer, pancreatic cancer, bone cancer, liver cancer, biliary cancer, urinary organ cancer (for example, bladder, testis), lymphoma, retinoblastoma, sarcoma, epidermal cancer, esophageal cancer, stomach cancer, cancer of the brain, cancer of the kidney, and metastasis thereof.

39. - 54. (Canceled)

55. (NEW) A method for inhibiting metastasis caused by cells expressing melanotransferrin (p97) at their surface, said method comprising the step of administering to a patient in need thereof exogenous soluble p97 or active fragment thereof, said soluble p97 or active fragment thereof being unconjugated to any moiety and competing with the p97 expressed on the cell surface, activating plasminogen in solution instead of membrane-bound plasminogen, thus preventing cell migration and preventing cancer cells from spreading.